Zai Lab Limited (NASDAQ:ZLAB) CFO Sells 9,618 Shares

Zai Lab Limited (NASDAQ:ZLAB - Get Free Report) CFO Yajing Chen sold 9,618 shares of the firm's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $30.00, for a total transaction of $288,540.00. Following the completion of the transaction, the chief financial officer now directly owns 17,429 shares in the company, valued at approximately $522,870. This represents a 35.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Yajing Chen also recently made the following trade(s):

• On Friday, April 4th, Yajing Chen sold 924 shares of Zai Lab stock. The shares were sold at an average price of $33.11, for a total value of $30,593.64.
• On Wednesday, April 2nd, Yajing Chen sold 5,280 shares of Zai Lab stock. The shares were sold at an average price of $35.89, for a total value of $189,499.20.

Zai Lab Stock Performance

Shares of Zai Lab stock traded up $1.57 on Friday, reaching $38.11. 1,056,017 shares of the company's stock were exchanged, compared to its average volume of 880,579. The company has a market capitalization of $4.20 billion, a P/E ratio of -13.76 and a beta of 0.96. The firm's 50-day moving average is $30.93 and its two-hundred day moving average is $30.08. Zai Lab Limited has a 52 week low of $16.01 and a 52 week high of $39.77.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.50) by $0.05. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. The company had revenue of $106.49 million for the quarter, compared to analysts' expectations of $118.40 million. On average, analysts expect that Zai Lab Limited will post -2.58 EPS for the current fiscal year.

Analyst Ratings Changes

ZLAB has been the subject of several research analyst reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zai Lab in a report on Thursday, March 27th. Bank of America reaffirmed a "neutral" rating and issued a $36.10 price objective (up from $29.00) on shares of Zai Lab in a research note on Monday, March 3rd. Scotiabank began coverage on shares of Zai Lab in a research report on Friday, March 7th. They set a "sector outperform" rating and a $55.00 target price for the company. Finally, JPMorgan Chase & Co. raised their price target on shares of Zai Lab from $44.00 to $51.00 and gave the stock an "overweight" rating in a report on Thursday, March 13th.

Institutional Trading of Zai Lab

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. bought a new position in shares of Zai Lab in the fourth quarter valued at $29,000. Pictet Asset Management Holding SA acquired a new stake in shares of Zai Lab in the 4th quarter worth about $31,000. Caitong International Asset Management Co. Ltd bought a new position in Zai Lab in the 1st quarter valued at about $75,000. Barclays PLC boosted its stake in Zai Lab by 337.6% during the 4th quarter. Barclays PLC now owns 3,702 shares of the company's stock valued at $97,000 after purchasing an additional 2,856 shares during the last quarter. Finally, Advisors Preferred LLC acquired a new position in Zai Lab during the 1st quarter valued at about $110,000. Institutional investors own 41.65% of the company's stock.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.